Autoantibodies in rheumatoid arthritis (RA) include rheumatoid factors (RFs) and anticitrullinated protein antibodies (ACPA), which are key diagnostic markers. Recent research has revealed that these autoantibodies play significant roles in RA pathogenesis. RFs target epitopes on IgG Fc regions, while ACPA recognize citrullinated proteins. IgA isotypes of RF and ACPA may provide prognostic information, as their presence is linked to reduced response to TNF inhibitors. ACPA also have variable domain glycans that may affect B cell activation and tolerance. ACPA can both contribute to joint destruction and have protective anti-inflammatory effects. ACPA-producing B cells are continuously activated, even in patients with clinical remission, which may lead to disease flares upon drug tapering. AMPAs, including ACPA, are associated with post-translational modifications of proteins, such as citrullination, carbamylation, and acetylation. ACPA and anti-carbamylated protein antibodies (anti-CarP) share similar reactivity patterns, while anti-acetylated protein antibodies (AAPA) are distinct. Recent studies show that ACPA can inhibit inflammation and arthritis in mouse models, suggesting a potential protective role. ACPA-producing B cells are persistently activated, indicating a continuous immune response in RA. Seronegative RA patients may also have autoantibodies against modified proteins, highlighting the complexity of RA autoantibodies. These findings suggest that autoantibodies, particularly IgA isotypes, are important in RA pathogenesis and may influence clinical outcomes. Further research is needed to fully understand the role of these autoantibodies in RA.Autoantibodies in rheumatoid arthritis (RA) include rheumatoid factors (RFs) and anticitrullinated protein antibodies (ACPA), which are key diagnostic markers. Recent research has revealed that these autoantibodies play significant roles in RA pathogenesis. RFs target epitopes on IgG Fc regions, while ACPA recognize citrullinated proteins. IgA isotypes of RF and ACPA may provide prognostic information, as their presence is linked to reduced response to TNF inhibitors. ACPA also have variable domain glycans that may affect B cell activation and tolerance. ACPA can both contribute to joint destruction and have protective anti-inflammatory effects. ACPA-producing B cells are continuously activated, even in patients with clinical remission, which may lead to disease flares upon drug tapering. AMPAs, including ACPA, are associated with post-translational modifications of proteins, such as citrullination, carbamylation, and acetylation. ACPA and anti-carbamylated protein antibodies (anti-CarP) share similar reactivity patterns, while anti-acetylated protein antibodies (AAPA) are distinct. Recent studies show that ACPA can inhibit inflammation and arthritis in mouse models, suggesting a potential protective role. ACPA-producing B cells are persistently activated, indicating a continuous immune response in RA. Seronegative RA patients may also have autoantibodies against modified proteins, highlighting the complexity of RA autoantibodies. These findings suggest that autoantibodies, particularly IgA isotypes, are important in RA pathogenesis and may influence clinical outcomes. Further research is needed to fully understand the role of these autoantibodies in RA.